21. Cascinu S, Labianca R, Barone C et al. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst 2007; 8: 601–607.
22. Bajetta E, Floriani I, Di Bartolomeo M et al. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. Ann Oncol 2014; 25: 1373–1378.
23. Schuhmacher C, Gretschel S, Lordick F et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954. J Clin Oncol 2010; 28(35): 5210–5218.
24. Becker K, Langer R, Reim D et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg 2011; 253(5): 934–939.
25. Jiang L, Yang KH, Guan QL et al. Survival benefit of neoadjuvant chemotherapy for resectable cancer of the gastric and gastroesophageal junction: a meta-analysis. J Clin Gastroenterol 2015; 5: 387–394.
26. Tsuburaya A, Yoshida K, Kobayashi M et al. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Lancet Oncol 2014; 15(8): 886–893.
27. Hartgrink HH, van de Velde CJH, Putter H et al. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol 2004; 6: 643–649.
28. Pauligk C, Tannapfel A, Meiler J et al. Pathological response to neoadjuvant 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: data from the phase II part of the FLOT4 phase III study of the AIO. J Clin Oncol 2015; 33(suppl): abstr 4016.

*Annals of Oncology* 27: 673–679, 2016
doi:10.1093/annonc/mdv625
Published online 7 January 2016

Downloaded from http://annonc.oxfordjournals.org/ at :: on April 28, 2016

# Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma†

S.-E. Al-Batran[1]*, E. Van Cutsem[2], S. C. Oh[3], G. Bodoky[4], Y. Shimada[5], S. Hironaka[6], N. Sugimoto[7], O. N. Lipatov[8], T.-Y. Kim[9], D. Cunningham[10], P. Rougier[11], K. Muro[12], A. M. Liepa[13], K. Chandrawansa[14], M. Emig[15], A. Ohtsu[16] & H. Wilke[17]

*[1]Institute of Clinical Cancer Research (IKF), UCT-University Cancer Center, Frankfurt, Germany; [2]University Hospitals Gasthuisberg, Leuven, Belgium; [3]Korea University Guro Hospital, Seoul, South Korea; [4]Szent László Hospital, Budapest, Hungary; [5]Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; [6]Department of Clinical Trial Promotion, Chiba Cancer Center, Chiba, Japan; [7]Department of Clinical Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; [8]Bashkortostan Clinical Oncology Center, Ufa, Russia; [9]Department of Internal Medicine and Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea; [10]Royal Marsden Hospital, Sutton, UK; [11]Hôpital Européen Georges Pompidou, Université Paris V, Paris, France; [12]Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan; [13]Eli Lilly and Company, Indianapolis, Indiana, USA; [14]Bayer HealthCare, Whippany, NJ, USA; [15]Eli Lilly and Company, Bad Homburg, Germany; [16]Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan; [17]Department of Oncology, Kliniken Essen Mitte Center of Pallative Care, Muenster University Clinic, Essen, Germany*

*Received 4 September 2015; revised 17 November 2015; accepted 18 December 2015*

**Background:** The phase III RAINBOW trial demonstrated that the addition of ramucirumab to paclitaxel improved overall survival, progression-free survival, and tumor response rate in fluoropyrimidine–platinum previously treated patients with

*Correspondence to: Dr Salah-Eddin Al-Batran, Institute of Clinical Cancer Research (IKF), UCT–University Cancer Center Frankfurt, Steinbacher Hohl 2-26, 60488 Frankfurt am Main, Germany. Tel: +069-76-01-4420; Fax: +069-76-01-3655; E-mail: albatran.salah@khnw.de

†Some of the quality-of-life results were presented as a poster presentation at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting, 30 May–3 June 2014, in Chicago, IL, and as an oral presentation at the European Society for Medical Oncology (ESMO) 16th World Congress on Gastrointestinal Cancer, 25–28 June 2014, in Barcelona, Spain. Data associated with the primary efficacy endpoints and baseline/end-of-treatment quality of life scores were published in *Lancet Oncol* 15:1224–1235, 2014.

© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com